This gene in particular has been suggested as a prognostic biomarker, as patients with strong expression levels had significantly poorer survival compared to those with negative-to-moderate MMP2 expression in a study conducted on tumor samples representing various stages of melanoma progression [18]. This evidence concerns the gene MMP2 and neoplasm.